Compare · MDLN vs SGP
MDLN vs SGP
Side-by-side comparison of Medline Inc. (MDLN) and SpyGlass Pharma Inc. (SGP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SGP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 52.7x SGP ($889.7M).
- Over the past year, MDLN is down 12.5% and SGP is up 1.8% - SGP leads by 14.4 points.
- MDLN has been more active in the news (12 items in the past 4 weeks vs 4 for SGP).
- MDLN has more recent analyst coverage (25 ratings vs 6 for SGP).
PerformanceMDLN-24.63%SGP+1.84%
2026-02-06+0.00%2026-08-25
- Company
- Medline Inc.
- SpyGlass Pharma Inc.
- Price
- $35.64+2.77%
- $26.59+0.91%
- Market cap
- $46.86B
- $889.7M
- 1M return
- -10.28%
- +26.62%
- 1Y return
- -12.54%
- +1.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2026
- News (4w)
- 12
- 4
- Recent ratings
- 25
- 6
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
Latest SGP
- Raymond James initiated coverage on SpyGlass Pharma with a new price target
- SEC Form 10-Q filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
- SpyGlass Pharma Appoints Shannon Treviño as General Counsel
- SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
- SpyGlass Pharma to Participate in Upcoming Investor Conferences
- SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
- SEC Form 10-Q filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits